Blockbuster SSRIs now becoming targets of safety questions

08/20/2004 | Forbes

The current questioning of the efficacy of selective serotonin reuptake inhibitors (SSRI) in the courts, by physicians, the Food and Drug Administration and lawmakers means drugs such as Paxil, Prozac and Zoloft have entered a new phase in the life of the drugs and are a problem for the pharmaceutical companies that make them. The drugs have become blockbusters for Pfizer, Eli Lilly, GlaxoSmithKline and other makers, but now those same companies face major questions about the drugs' safety.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ